HK1258509A1 - Gitr激动剂 - Google Patents

Gitr激动剂 Download PDF

Info

Publication number
HK1258509A1
HK1258509A1 HK19100858.0A HK19100858A HK1258509A1 HK 1258509 A1 HK1258509 A1 HK 1258509A1 HK 19100858 A HK19100858 A HK 19100858A HK 1258509 A1 HK1258509 A1 HK 1258509A1
Authority
HK
Hong Kong
Prior art keywords
polypeptides
gitr
variable domains
single variable
present
Prior art date
Application number
HK19100858.0A
Other languages
English (en)
Chinese (zh)
Inventor
Pieter DESCHAGHT
Sandra LI
Veerle Snoeck
Jan Pype
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of HK1258509A1 publication Critical patent/HK1258509A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK19100858.0A 2015-10-22 2016-10-24 Gitr激动剂 HK1258509A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562245188P 2015-10-22 2015-10-22
US62/245,188 2015-10-22
US201662276352P 2016-01-08 2016-01-08
US62/276,352 2016-01-08
PCT/EP2016/075558 WO2017068186A1 (en) 2015-10-22 2016-10-24 Gitr agonists

Publications (1)

Publication Number Publication Date
HK1258509A1 true HK1258509A1 (zh) 2019-11-15

Family

ID=57211500

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100858.0A HK1258509A1 (zh) 2015-10-22 2016-10-24 Gitr激动剂

Country Status (8)

Country Link
US (2) US11059899B1 (enExample)
EP (1) EP3365371B1 (enExample)
JP (1) JP7084870B2 (enExample)
CN (1) CN108473579B (enExample)
AU (1) AU2016341403B2 (enExample)
CA (1) CA3002711A1 (enExample)
HK (1) HK1258509A1 (enExample)
WO (1) WO2017068186A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2753439C2 (ru) 2015-07-23 2021-08-16 Инхибркс, Инк. Поливалетные и полиспецифичные gitr-связывающие слитые белки
JP7084870B2 (ja) 2015-10-22 2022-06-15 アブリンクス エン．ヴェー． Ｇｉｔｒアゴニスト
TWI895621B (zh) 2016-05-27 2025-09-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
EP3478721A1 (en) 2016-07-01 2019-05-08 Five Prime Therapeutics, Inc. Combined anti tumor therapy with a gitr agonist and cpg
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
KR20200006115A (ko) 2017-05-16 2020-01-17 브리스톨-마이어스 스큅 컴퍼니 항-gitr 효능제 항체에 의한 암의 치료
CN110461874B (zh) 2017-06-30 2022-04-12 江苏恒瑞医药股份有限公司 抗gitr抗体、其抗原结合片段及其医药用途
CN110357958A (zh) * 2018-03-26 2019-10-22 信达生物制药(苏州)有限公司 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用
CN113105546B (zh) * 2018-06-06 2022-02-08 暨南大学 一种抗重组人碱性成纤维细胞生长因子纳米抗体及其应用
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
IL293561A (en) 2019-12-06 2022-08-01 Ablynx Nv Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23
KR20230123497A (ko) * 2020-12-18 2023-08-23 아블린쓰 엔.브이. IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드
CN112851811B (zh) * 2021-01-28 2022-08-09 姜国胜 一种cd44v6纳米抗体及其作为白血病研究试剂的应用
AU2022272117A1 (en) * 2021-05-10 2024-01-04 Medimabbio Inc. Anti-gitr antibodies and uses thereof
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
CA3260559A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant D protein and a component of TNFSF
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
US20250270274A1 (en) * 2024-02-26 2025-08-28 Serpentide Inc. Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1809589A (zh) * 2003-05-23 2006-07-26 Wyeth公司 Gitr配体和gitr配体相关分子和抗体及其应用
CN101218257A (zh) * 2005-03-25 2008-07-09 托勒克斯股份有限公司 Gitr结合分子及其用途
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
CN102574924A (zh) * 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
TW201605896A (zh) * 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
TW202132337A (zh) 2014-05-28 2021-09-01 美商艾吉納斯公司 抗糖皮質素誘導性ｔｎｆｒ家族相關性受體（ｇｉｔｒ）抗體類及使用彼等之方法
AU2015271709B2 (en) 2014-06-06 2020-11-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
CA2988115A1 (en) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
RU2753439C2 (ru) * 2015-07-23 2021-08-16 Инхибркс, Инк. Поливалетные и полиспецифичные gitr-связывающие слитые белки
JP7084870B2 (ja) 2015-10-22 2022-06-15 アブリンクス エン．ヴェー． Ｇｉｔｒアゴニスト

Also Published As

Publication number Publication date
JP2018537421A (ja) 2018-12-20
US11059899B1 (en) 2021-07-13
US11919966B2 (en) 2024-03-05
AU2016341403B2 (en) 2023-08-03
CA3002711A1 (en) 2017-04-27
JP7084870B2 (ja) 2022-06-15
WO2017068186A1 (en) 2017-04-27
CN108473579B (zh) 2022-03-01
WO2017068186A9 (en) 2017-06-22
US20220411521A1 (en) 2022-12-29
AU2016341403A1 (en) 2018-05-10
EP3365371A1 (en) 2018-08-29
CN108473579A (zh) 2018-08-31
EP3365371C0 (en) 2025-10-08
EP3365371B1 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
HK1258509A1 (zh) Gitr激动剂
ZA202308846B (en) Cx3cr1-binding polypeptides
WO2015112886A3 (en) Binding proteins and methods of use thereof
MX2024003743A (es) Inmunoglobulinas de union a agrecano.
EP4289484A3 (en) Anti-ctla-4 antibodies and methods of use thereof
PH12019500596B1 (en) Recombinant binding proteins and their use
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
WO2015109124A3 (en) Immunomodulatory agents
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
PH12018501114A1 (en) Polypeptides inhibiting cd40l
MY188879A (en) Glycan therapeutics and related methods thereof
HK1254880A1 (zh) 抗pd-1抗体及其应用
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
MX384075B (es) Nuevas proteínas específicas para la angiogénesis.
WO2017015619A8 (en) Antibodies to coagulation factor xia and uses thereof
WO2016063026A3 (en) Selective nav protein binders
WO2019014360A8 (en) POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF
WO2017019957A3 (en) Binding proteins and methods of use thereof
WO2016020880A3 (en) Angiopoietin-like 4 antibodies and methods of use
PH12019501108A1 (en) Anti-gitr anti-binding protein and methods of use thereof
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.
WO2017044866A3 (en) Enhanced delivery of drugs to the brain
WO2016075305A3 (en) Peptides derived from acinetobacter baumannii and their use in vaccination
WO2016040767A3 (en) Chrdl-1 epitopes and antibodies